Reference: Tazorac Cream, 0.05% — Competitive Intelligence Brief

Reference: Tazorac Cream, 0.05% (Reference: Tazorac Cream, 0.05%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Retinoid. Area: Dermatology.

phase 3 Retinoid Retinoic acid receptors Dermatology Small molecule

Target snapshot

Reference: Tazorac Cream, 0.05% (Reference: Tazorac Cream, 0.05%) — G & W Laboratories Inc.. Tazorac Cream, 0.05% is a topical retinoid that works by promoting cell turnover and preventing the formation of comedones, thereby reducing acne severity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Reference: Tazorac Cream, 0.05% TARGET	Reference: Tazorac Cream, 0.05%	G & W Laboratories Inc.	phase 3	Retinoid	Retinoic acid receptors
Adapalene + benzoyl peroxide samples	Adapalene + benzoyl peroxide samples	Wake Forest University	marketed	Retinoid + peroxide combination	Retinoic acid receptors (adapalene); bacterial cell membrane and proteins (benzoyl peroxide)
Adapalene/benzoyl peroxide gel, 0.1%/2.5%	Adapalene/benzoyl peroxide gel, 0.1%/2.5%	Galderma R&D	marketed	Retinoid + peroxide combination	Retinoic acid receptors (adapalene); bacterial cell membrane and proteins (benzoyl peroxide)
Tretinoin cream 0.005%	Tretinoin cream 0.005%	Hexsel Dermatology Clinic	marketed	Retinoid	Retinoic acid receptors (RAR-α, RAR-β, RAR-γ)
adapalene gel, 0.3%	adapalene gel, 0.3%	Galderma R&D	marketed	Retinoid (third-generation)	Retinoic acid receptors (RARγ, RARα, RARβ)
Duobrii®	Duobrii®	Icahn School of Medicine at Mount Sinai	marketed	Topical corticosteroid and retinoid combination	Glucocorticoid receptor (halobetasol); retinoic acid receptors (tazarotene)
adapalene/benzoyl peroxide	adapalene/benzoyl peroxide	Galderma R&D	marketed	Retinoid + peroxide combination	Retinoic acid receptors (adapalene); bacterial cell membrane and proteins (benzoyl peroxide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Retinoid class)

1. Galderma R&D · 8 drugs in this class
2. Bausch Health Americas, Inc. · 4 drugs in this class
3. Stiefel, a GSK Company · 2 drugs in this class
4. Army Medical University, China · 1 drug in this class
5. Centro Dermatológico Dr. Ladislao de la Pascua · 1 drug in this class
6. Cipher Pharmaceuticals Inc. · 1 drug in this class
7. Center for Sight Las Vegas · 1 drug in this class
8. Dr. Reddy's Laboratories Limited · 1 drug in this class
9. Dr.dr.Irma Bernadette, SpKK (K) · 1 drug in this class
10. Dr. Emmy Graber · 1 drug in this class